Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01663987 · ClinicalTrials.gov registry record · Phase 4
Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1
A Phase 4 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 4
- Development phase
- 79
- Enrollment target
NCT01663987 is a Phase 4 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 79 participants.
The verdict
NCT01663987, a Phase 4 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 79 participants
- Enrollment target
Study Summary
A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge 1)
Interventions
- DRUG Placebo
- DRUG tiotropium bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2012-08-01 |
| Est. Completion | 2014-05-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01663987
The ClinicalTrials.gov registry entry for NCT01663987 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01663987 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01663987 about?
NCT01663987 is a clinical study titled "Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1". A randomized, placebo-controlled, double-blind, parallel group, multi center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospita...
What is the current status of trial NCT01663987?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 79 participants. The study started on 2012-08-01. Estimated completion is 2014-05-01.
What interventions are being tested in trial NCT01663987?
The interventions under investigation include: Placebo (DRUG), tiotropium bromide (DRUG).
Who is sponsoring clinical trial NCT01663987?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.